Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor

Cancer Letters

Volumn 293, Issue 1, 2010, Pages 124-131

  Gheeya, Jinesh ^a   Johansson, Peter ^a   Chen, Qing Rong ^a   Dexheimer, Thomas ^a   Metaferia, Belhu ^a   Song, Young K ^a   Wei, Jun S ^a   He, Jianbin ^a   Pommier, Yves ^a   Khan, Javed ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti cancer drug; CMAP; EAD; Microarray; Neuroblastoma; Topoisomerase

Indexed keywords

AMONAFIDE; ANTHRAQUINONE DERIVATIVE; CAMPTOTHECIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; DOXORUBICIN; ECHINOMYCIN; ELLIPTICINE; HYCANTHONE; IRINOTECAN; MESSENGER RNA; MITOXANTRONE; PHENOXYBENZAMINE; TRICHOSTATIN A;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA ALKYLATION; DNA CLEAVAGE; DNA MICROARRAY; DNA REPLICATION; DNA STRAND BREAKAGE; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SCORING SYSTEM; UPREGULATION;

ALKYLATION; ANTHRAQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; DATABASES, GENETIC; DNA DAMAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EPOXY COMPOUNDS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER;

EID: 77952424291     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.004     Document Type: Article

References (25)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3:203-216.
2. Cohn S.L., Pearson A.D., London W.B., Monclair T., Ambros P.F., Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., Mosseri V., Simon T., Garaventa A., Castel V., Matthay K.K. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J. Clin. Oncol. 2009, 27:289-297.
3. A.L. Yu, A.L. Gilman, M.F. Ozkaynak, W.B. London, S. Kreissman, H.X. Chen, K.K. Matthay, S.L. Cohn, J.M. Maris, P. Sondel, A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: children's oncology group (COG) study ANBL0032, ASCO Annual Meeting, 2009 p. 15.
4. Trial watch: Immunotherapy shows promise in phase III neuroblastoma trial, Nat. Rev. Drug Discov. 8 (2009) 604.
5. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
6. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., Maloney K.N., Clardy J., Hahn W.C., Chiosis G., Golub T.R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10:321-330.
7. Bhattacharyya R.P., Remenyi A., Good M.C., Bashor C.J., Falick A.M., Lim W.A. The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. Science 2006, 311:822-826.
8. De Preter K., De Brouwer S., Van Maerken T., Pattyn F., Schramm A., Eggert A., Vandesompele J., Speleman F. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin. Cancer Res. 2009, 15:3690-3696.
9. Gheeya J.S., Chen Q.R., Benjamin C.D., Cheuk A.T., Tsang P., Chung J.Y., Metaferia B.B., Badgett T.C., Johansson P., Wei J.S., Hewitt S.M., Khan J. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol. Ther. 2009, 8.
10. Pourquier P., Jensen A.D., Gong S.S., Pommier Y., Rogler C.E. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Res. 1999, 27:1919-1925.
11. Dexheimer T.S., Kozekova A., Rizzo C.J., Stone M.P., Pommier Y. The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA-topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts. Nucleic Acids Res. 2008, 36:4128-4136.
12. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., Pommier Y. GammaH2AX and cancer. Nat. Rev. Cancer 2008, 8:957-967.
13. Dexheimer T.S., Pommier Y. DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat. Protoc. 2008, 3:1736-1750.
14. Mattes W.B., Hartley J.A., Kohn K.W. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res. 1986, 14:2971-2987.
15. Izbicka E., Izbicki T. Therapeutic strategies for the treatment of neuroblastoma. Curr. Opin. Investig. Drugs 2005, 6:1200-1214.
16. Takano S., Gately S., Jiang J.B., Brem S. A diaminoantraquinone inhibitor of angiogenesis. J. Pharmacol. Exp. Ther. 1994, 271:1027-1033.
17. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
18. Nitiss J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9:338-350.
19. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 2009, 109:2894-2902.
20. Chiba T., Yokosuka O., Fukai K., Kojima H., Tada M., Arai M., Imazeki F., Saisho H. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor trichostatin A, on human hepatoma cells. Oncology 2004, 66:481-491.
21. Tellez J.F., Carvajal K., Cruz D., Carabez A., Chavez E. Effect of perezone on arrhythmias and markers of cell injury during reperfusion in the anesthetized rat. Life Sci. 1999, 65:1615-1623.
22. Farhana L., Dawson M.I., Fontana J.A. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res. 2005, 65:4909-4917.
23. Lyss G., Knorre A., Schmidt T.J., Pahl H.L., Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J. Biol. Chem. 1998, 273:33508-33516.
24. Huang P.R., Yeh Y.M., Wang T.C. Potent inhibition of human telomerase by helenalin. Cancer Lett. 2005, 227:169-174.
25. Dai Y., Grant S. CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins. Cancer Biol. Ther. 2006, 5:171-173.